Both in Biotechnology
Maze Therapeutics vs Novavax
Over the past year MAZE returned −3.0% and NVAX returned +22.4%; their daily moves had a correlation of 0.18.
MAZE −3.0% NVAX +22.4%Growth of $1, one year, split-adjusted
| Metric | MAZE | NVAX |
|---|---|---|
| Price | $32.25 | $9.68 |
| Market cap | $1.79B | $1.60B |
| Today | +6.19% | +1.57% |
| 1 month | +22.0% | −22.9% |
| 6 months | +21.4% | +19.5% |
| Year to date | −22.2% | +44.0% |
| 1 year | −2.0% | +15.2% |
| Revenue growth (YoY) | — | −76.3% |
| Gross margin | — | 74.9% |
| Net margin | — | −94.2% |
| P/E (TTM) | — | — |
| Price / sales | 89.6× | 3.9× |
| Net cash | $372.1M | $422.0M |
| Dividend yield | — | — |
| Volatility (60d) | 67.4% | 80.6% |
| Short % of float | 18.8% | 30.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).